- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Biosimilar Developer Polus Gains $9.37 Million Investment
Republic of Korea–based drug developer Polus has sold $9.37 million in convertible bonds to its affiliate Amnis.
Republic of Korea—based drug developer Polus has sold $9.37 million in convertible bonds to its affiliate Amnis, according to The Investor.
Polus plans to use its newly raised funds to complete the construction of its new Korean manufacturing plant located in Gyeonggi province. The company broke ground on the plant in February 2017 in the hopes of completing the facility by February 2018. Polus also plans to set up a production site in Turkey that will supply Polus’ biosimilar products to the European marketplace (Polus will reportedly seek US and European regulatory approval for the biosimilars in its pipeline).
Polus, founded in March 2016 and led by CEO Nam Seung-heon (formerly the vice president and president of rival Korean biosimilar developer Celltrion and Celltrion Healthcare, respectively), is currently developing 4 biosimilar candidates: PDP808, an insulin glargine (referenced on Lantus); PDP805, a somatropin (human growth hormone); PDP807, a ranibizumab (referenced on Lucentis); and PDP815, an insulin lispro (referenced on Humalog).
The major investment from Amnis comes after a July 2017 announcement that Polus would issue private placement corporate bonds, including convertible bonds and bonds with stock purchase warrants, worth the equivalent of $43.44 million. The company also announced that it would offer $34.76 million worth of corporate bonds without guarantees. At the time, Polus’ president, Park Joo-ho, told Business Korea that, in addition to completing work on its manufacturing facility, the funds raised would allow the company to begin a global clinical trial of its insulin glargine biosimilar by the middle of 2018.
As for Amnis, the newly announced investment in Polus may mark a significant change for the company; an Amnis official told The Investor that the company, which is currently focused on the production of telecommunication equipment, “may spin off our telecom equipment business later” as the company shifts its focus to biopharmaceuticals. Amnis is scheduled to convene a general meeting on January 26 to vote on changing its name to Polus Biopharm.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
